DADC
RXII

D.A. Davidson & Co’s GALENA BIOPHARMA INC COM RXII Stock Holding History

D.A. Davidson & Co’s Portfolio RXII Stock Details RXII Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-8,500
Closed -$11K – 2481
2016
Q1 		$11K Buy
+8,500
New +$11K ﹤0.01% 1898

Other funds holding RXII

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
BIM
BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

D.A. Davidson & Co's RXII Position: Q2 2016 in Review

D.A. Davidson & Co sold out of GALENA BIOPHARMA INC COM (RXII) in Q2 2016, closing a stake of 8,500 shares — an estimated $11K sold.

D.A. Davidson & Co first reported a position in RXII in Q1 2016 and held it in 1 quarter. The position peaked at $11K in Q1 2016. 90 funds tracked by Wall St. Rank hold RXII as of Q2 2016.

  • D.A. Davidson & Co reported no remaining GALENA BIOPHARMA INC COM position as of Q2 2016 after selling out during the quarter.
  • D.A. Davidson & Co sold 8,500 GALENA BIOPHARMA INC COM shares in Q2 2016, an estimated $11K.
  • D.A. Davidson & Co first reported a position in GALENA BIOPHARMA INC COM in Q1 2016 and held it in 1 quarter.
  • D.A. Davidson & Co's GALENA BIOPHARMA INC COM position peaked at $11K in Q1 2016.
  • 90 funds tracked by Wall St. Rank held GALENA BIOPHARMA INC COM as of Q2 2016.

Based on D.A. Davidson & Co's 13F filing for Q2 2016, filed 15 Aug 2016.